While advances in medicine, technology and healthcare services offer promises of longevity and improved quality of life (QoL), there is also increasing reliance on a patient׳s skills and motivation to optimize all the benefits available. Patient engagement in their own healthcare has been described as the 'blockbuster drug of the century'. In multiple sclerosis (MS), patient engagement is vital if outcomes for the patient, society and healthcare systems are to be optimized. The MS in the 21st Century Steering Group devised a set of themes that require action with regard to patient engagement in MS, namely: 1) setting and facilitating engagement by education and confidence-building; 2) increasing the importance placed on QoL and patient concerns through patient-reported outcomes (PROs); 3) providing credible sources of accurate information; 4) encouraging treatment adherence through engagement; and 5) empowering through a sense of responsibility. Group members independently researched and contributed examples of patient engagement strategies from several countries and examined interventions that have worked well in areas of patient engagement in MS, and other chronic illnesses. The group presents their perspective on these programs, discusses the barriers to achieving patient engagement, and suggests practical strategies for overcoming these barriers. With an understanding of the issues that influence patient engagement in MS, we can start to investigate ways to enhance engagement and subsequent health outcomes. Engaging patients involves a broad, multidisciplinary approach.

Blizard Institute Bart׳s School of Medicine and Dentistry London UK

CHUM Research Centre Montreal Quebec Canada

European Charcot Foundation Molenhoek The Netherlands

European Health Economics Spéracèdes France

General Faculty Hospital Charles University Prague Czech Republic

Kliniken Valens Valens Switzerland

Moscow MS Centre Russian State Research Medical University named by NI Pirogov Moscow Russia

Northern Ireland Neurology Service Portadown UK

Rehabilitation in MS Brussels Belgium

Royal Holloway University of London Egham UK

Sozialstiftung Bamberg Hospital Bamberg Germany

Tampere University Hospital Tampere Finland

Università di Roma Tor Vergata Rome Italy

Universitätsspital Zürich Zürich Switzerland

University Hospital of Lille Lille France

University Hospital San Carlos Madrid Spain

Western University London Ontario Canada

000      

00000naa a2200000 a 4500

001      

bmc16010156

003      

CZ-PrNML

005      

20160520111406.0

007      

ta

008      

160408s2015 ne f 000 0|engg|

009      

AR

024    7_

$a 10.1016/j.msard.2015.02.005 $2 doi

024    7_

$a 10.1016/j.msard.2015.02.005 $2 doi

035    __

$a (PubMed)26008937

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Rieckmann, Peter $u Sozialstiftung Bamberg Hospital, Bamberg, Germany. Electronic address: peter.rieckmann@sozialstiftung-bamberg.de.

245    10

$a Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group / $c P. Rieckmann, A. Boyko, D. Centonze, I. Elovaara, G. Giovannoni, E. Havrdová, O. Hommes, J. Kesselring, G. Kobelt, D. Langdon, J. LeLorier, SA. Morrow, C. Oreja-Guevara, S. Schippling, C. Thalheim, H. Thompson, P. Vermersch,

520    9_

$a While advances in medicine, technology and healthcare services offer promises of longevity and improved quality of life (QoL), there is also increasing reliance on a patient׳s skills and motivation to optimize all the benefits available. Patient engagement in their own healthcare has been described as the 'blockbuster drug of the century'. In multiple sclerosis (MS), patient engagement is vital if outcomes for the patient, society and healthcare systems are to be optimized. The MS in the 21st Century Steering Group devised a set of themes that require action with regard to patient engagement in MS, namely: 1) setting and facilitating engagement by education and confidence-building; 2) increasing the importance placed on QoL and patient concerns through patient-reported outcomes (PROs); 3) providing credible sources of accurate information; 4) encouraging treatment adherence through engagement; and 5) empowering through a sense of responsibility. Group members independently researched and contributed examples of patient engagement strategies from several countries and examined interventions that have worked well in areas of patient engagement in MS, and other chronic illnesses. The group presents their perspective on these programs, discusses the barriers to achieving patient engagement, and suggests practical strategies for overcoming these barriers. With an understanding of the issues that influence patient engagement in MS, we can start to investigate ways to enhance engagement and subsequent health outcomes. Engaging patients involves a broad, multidisciplinary approach.

650    _2

$a lidé $7 D006801

650    _2

$a motivace $7 D009042

650    _2

$a roztroušená skleróza $x psychologie $x terapie $7 D009103

650    12

$a zapojení pacienta $7 D010358

650    12

$a péče orientovaná na pacienta $7 D018802

650    _2

$a kvalita života $7 D011788

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Boyko, Alexey $u Moscow MS Centre, Russian State Research Medical University named by NI Pirogov, Moscow, Russia.

700    1_

$a Centonze, Diego $u Università di Roma Tor Vergata, Rome, Italy.

700    1_

$a Elovaara, Irina $u Tampere University Hospital, Tampere, Finland.

700    1_

$a Giovannoni, Gavin $u Blizard Institute, Bart׳s School of Medicine and Dentistry, London, UK.

700    1_

$a Havrdová, Eva $u General Faculty Hospital, Charles University, Prague, Czech Republic.

700    1_

$a Hommes, Otto $u European Charcot Foundation, Molenhoek, The Netherlands.

700    1_

$a Kesselring, Jurg $u Kliniken Valens, Valens, Switzerland.

700    1_

$a Kobelt, Gisela $u European Health Economics, Spéracèdes, France.

700    1_

$a Langdon, Dawn $u Royal Holloway, University of London, Egham, UK.

700    1_

$a LeLorier, Jacques $u CHUM Research Centre, Montreal, Quebec, Canada.

700    1_

$a Morrow, Sarah A $u Western University, London, Ontario, Canada.

700    1_

$a Oreja-Guevara, Celia $u University Hospital San Carlos, Madrid, Spain.

700    1_

$a Schippling, Sven $u Universitätsspital Zürich, Zürich, Switzerland.

700    1_

$a Thalheim, Christoph $u Rehabilitation in MS (RIMS), Brussels, Belgium.

700    1_

$a Thompson, Heidi $u Northern Ireland Neurology Service, Portadown, UK.

700    1_

$a Vermersch, Patrick $u University Hospital of Lille, Lille, France.

773    0_

$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 4, č. 3 (2015), s. 202-18

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26008937 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160408 $b ABA008

991    __

$a 20160520111519 $b ABA008

999    __

$a ok $b bmc $g 1113585 $s 934524

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 4 $c 3 $d 202-18 $e 20150302 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780

LZP    __

$a Pubmed-20160408